Trial Profile
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Tilsotolimod (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms ILLUMINATE-301
- Sponsors Aceragen; Idera Pharmaceuticals
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 21 Sep 2021 This trial is been terminated due to lack of efficacy, according to ClinicalTrials.gov record.
- 11 Aug 2021 This trial has been completed in France (End Date: 01 Jun 2021), according to European Clinical Trials Database record